PPARG and metabolic dysfunction-associated steatohepatitis: These protective effects of HDL on MASH were previously reported in the Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Non-alcoholic Steatohepatitis (PIVENS) trial, where the prominent role of the PPARγ agonist pioglitazone in the elevation of HDL levels was reported.